Huntington’s Disease Clinical Trials Corner: August 2023-Reference-Cited by-同舟云学术

Huntington’s Disease Clinical Trials Corner: August 2023

Published:2023-07-28 Issue:2 Volume:12 Page:169-185
ISSN:1879-6397
Container-title:Journal of Huntington's Disease
language:
Short-container-title:JHD

Author:

Estevez-Fraga Carlos¹,Tabrizi Sarah J.¹,Wild Edward J.¹

Affiliation:

1. Huntington’s Disease Centre, UCL Queen Square Institute of Neurology, London, UK

Abstract

In this edition of the Huntington’s Disease Clinical Trials Corner, we expand on the GENERATION HD2 (tominersen) and on the Asklepios Biopharmaceutical/BrainVectis trial with AB-1001. We also comment on the recent findings from the PROOF-HD trial, and list all currently registered and ongoing clinical trials in Huntington’s disease.

Publisher

IOS Press

Subject

Cellular and Molecular Neuroscience,Neurology (clinical)

Reference33 articles.

1. Hoffmann-La Roche A Study to Evaluate the Safety, Biomarkers, and Efficacy of Tominersen Compared With Placebo in Participants With Prodromal and Early Manifest Huntington’s Disease. 2023. https://clinicaltrials.gov/ct2/show/NCT05686551.

2. Asklepios BioPharmaceutical. A Study to Evaluate AB-Striatal Administration in Adults With Early Manifest Huntington’s Disease. 2022. https://clinicaltrials.gov/ct2/show/NCT05541627.

3. Prilenia. PRidopidine’s Outcome On Function in Huntington Disease, PROOF-HD. 2022. https://clinicaltrials.gov/ct2/show/NCT04556656.

4. Clinical Trials Corner: September 2017;Rodrigues;J Huntingtons Dis,2017

5. A biological classification of Huntington’s disease: the Integrated Staging System;Tabrizi;Lancet Neurol,2022

Cited by 16 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Huntingtin lowering impairs the maturation and synchronized synaptic activity of human cortical neuronal networks derived from induced pluripotent stem cells;Neurobiology of Disease;2024-10

2. Time to Functional Loss as an Endpoint in Huntington's Disease Trials: Enrichment and Sample Size;Movement Disorders;2024-08-05

3. Epidemiology of Huntington's Disease in Latin America: A Systematic Review and Meta‐Analysis;Movement Disorders;2024-07-23

4. Profiling deutetrabenazine extended-release tablets for tardive dyskinesia and chorea associated with Huntington’s disease;Expert Review of Neurotherapeutics;2024-07-09

5. Immune responses to central nervous system directed adeno-associated virus gene therapy: Does direct CNS delivery make a difference?;Neurotherapeutics;2024-07